Captopril, the first orally active inhibitor of angiotensin-converting enzyme, is used widely in
the treatment of hypertension and congestive heart failure. The pharmacokinetics of this …

Captopril is an orally active inhibitor of angiotensin-converting enzyme (ACE) and has been
widely studied in the treatment of patients with mild to moderate essential hypertension …

The advancement in the processing speeds of computing machines has facilitated the
development of complex physiologically based pharmacokinetic (PBPK) models. These …

Objectives Serum angiotensin-converting enzyme (ACE) is the only biomarker routinely
used in the laboratory diagnostics of sarcoidosis, and ACE inhibitor (ACEi) drugs are among …

Catecholamines have been demonstrated to be cardiotoxic. Besides hemodynamic
alterations, oxygen free radicals generated by the auto-oxidation of catecholamines might …

Adverse drug effects on the cardiovascular system are a major cause of compound attrition
throughout compound discovery and development. There are many ways by which drugs …

The inter-relationship between the pharmacokinetic and pharmacodynamic behaviour of
ACE inhibitors is reviewed. First, some of the methods which have been used to assess the …

Background/Aim: The renin-angiotensin system (RAS) regulates blood pressure. The RAS is
also related to cell growth, and its activation has been reported in various cancer cells …

Angiotensin-converting enzyme inhibition has proven to be a successful approach for the
long-term treatment of patients with congestive heart failure. This investigation compared the …

This review summarizes the evidence indicating that local synthesis of angiotensin II, and
interference with this process by inhibition of angiotensin-converting enzyme (ACE), may be …